Integration of olanzapine determinations in a HPLC-diode array detection system for routine psychotropic drug monitoring

Centre Medico Psychologique B, CHU G. Montpied, BP39 63003, Clermont-Ferrand Cedex 3, France.
Clinical Chemistry (Impact Factor: 7.91). 10/2001; 47(9):1719-21.
Source: PubMed
Download full-text


Available from: P.-M. Llorca, Mar 29, 2014
1 Follower
25 Reads
  • Source
    Clinical Chemistry 01/2004; 49(12):2088-91. DOI:10.1373/clinchem.2003.022517 · 7.91 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There are limited data regarding the use of atypical antipsychotic medications in pregnancy. The objectives of the current study were to quantify placental permeability to antipsychotic medications and to document obstetrical outcomes for women taking these agents proximate to delivery. The authors conducted a prospective observational study of women treated with an atypical antipsychotic or haloperidol during pregnancy. Maternal and umbilical cord plasma samples collected at delivery were analyzed for medication concentrations. Placental passage was defined as the ratio of umbilical cord to maternal plasma concentrations (ng/ml). Obstetrical outcome was ascertained through maternal reports and reviews of obstetrical records. Fifty-four pregnant women with laboratory-confirmed antipsychotic use proximate to delivery were included in the analysis. Complete maternal-infant sample pairs were available for 50 participants. Placental passage ratio was highest for olanzapine (mean=72.1%, SD=42.0%), followed by haloperidol (mean=65.5%, SD=40.3%), risperidone (mean=49.2%, SD=33.9%), and quetiapine (mean=23.8%, SD=11.0%). There were tendencies toward higher rates of low birth weight (30.8%) and neonatal intensive care unit admission (30.8%) among neonates exposed to olanzapine. All four antipsychotics demonstrated incomplete placental passage. Quetiapine demonstrated the lowest placental passage of the medications studied. These novel data provide an initial quantification of the placental passage of antipsychotics and fetal exposure in humans, demonstrating significant differences between individual medications.
    American Journal of Psychiatry 09/2007; 164(8):1214-20. DOI:10.1176/appi.ajp.2007.06111886 · 12.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: An RP-HPLC method for the simultaneous separation and determination of olanzapine (OLZ) and its process impurities in bulk drugs and pharmaceutical formulations was developed. The separation was accomplished on Inertsil ODS 3V (4.6 mm x 250 mm; particle size 5 microm) column using 0.2 M ammonium acetate (pH = 4.50) and ACN as mobile phase in gradient elution mode. The analytes were monitored by a photo diode array (PDA) detector set at 254 nm and the flow rate was kept at 1.0 mL/min. The chromatographic behavior of all the compounds was examined under variable compositions of different solvents, buffer concentrations, and pH. The method was validated in terms of accuracy, precision, and linearity. Four unknown process impurities observed consistently during the analysis of different batches of OLZ were isolated and characterized by ESI-MS/MS, (1)H NMR, and FT-IR. The proposed RP-HPLC method was successfully applied to the analysis of commercial formulations. The method could be of use not only for rapid and routine evaluation of the quality of OLZ in bulk drug manufacturing units but also for the detection of its impurities in pharmaceutical formulations.
    Journal of Separation Science 01/2008; 31(1):107-18. DOI:10.1002/jssc.200700397 · 2.74 Impact Factor
Show more